GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pressure BioSciences Inc (OTCPK:PBIO) » Definitions » EBIT

Pressure BioSciences (Pressure BioSciences) EBIT : $-5.77 Mil (TTM As of Sep. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Pressure BioSciences EBIT?

Pressure BioSciences's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was $-1.29 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was $-5.77 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pressure BioSciences's annualized ROC % for the quarter that ended in Sep. 2023 was -24.31%. Pressure BioSciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -1,986.15%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Pressure BioSciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -21.37%.


Pressure BioSciences EBIT Historical Data

The historical data trend for Pressure BioSciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pressure BioSciences EBIT Chart

Pressure BioSciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.53 -6.60 -7.66 -5.70 -5.64

Pressure BioSciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.43 -0.47 -2.96 -1.04 -1.29

Competitive Comparison of Pressure BioSciences's EBIT

For the Medical Devices subindustry, Pressure BioSciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pressure BioSciences's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pressure BioSciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pressure BioSciences's EV-to-EBIT falls into.



Pressure BioSciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pressure BioSciences  (OTCPK:PBIO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pressure BioSciences's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

ROC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=-5.172 * ( 1 - 0% )/( (20.379 + 22.177)/ 2 )
=-5.172/21.278
=-24.31 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Pressure BioSciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-5.164/( ( (0.269 + max(-6.356, 0)) + (0.251 + max(-7.975, 0)) )/ 2 )
=-5.164/( ( 0.269 + 0.251 )/ 2 )
=-5.164/0.26
=-1,986.15 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.189 + 0.554 + 0.281) - (6.789 + 0.302 + 0.289)
=-6.356

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.329 + 0.467 + 0.22) - (8.362 + 0.253 + 0.376)
=-7.975

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Pressure BioSciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2023 )
=-5.767/26.987
=-21.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pressure BioSciences EBIT Related Terms

Thank you for viewing the detailed overview of Pressure BioSciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Pressure BioSciences (Pressure BioSciences) Business Description

Traded in Other Exchanges
N/A
Address
14 Norfolk Avenue, South Easton, MA, USA, 02375
Pressure BioSciences Inc is engaged in the healthcare division. The firm is a leader in the development & sale of innovative, enabling, pressure-based platform solutions for the worldwide life sciences industry. The company has developed and patented a technology platform that can control the sample preparation process. This process, called pressure cycling technology (PCT), uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels. The company is also the distributor of the Constant Systems (CS) cell disruption equipment, parts, and consumables. Its products include Barocyclers, External Pressure Calibration Device Kits, MicroTubes, HUB High-Pressure Generators, and Accessories.
Executives
Daniel Joseph Shea officer: Senior Vice President & CFO 2 MINUTEMAN ROAD, MEDFIELD MA 02052
Bradford Addison Young officer: Chief Commercial Officer 513 LITTLE JOHN HILL, ANNAPOLIS MD 21405
Richard T Schumacher director, officer: Chief Executive Officer 375 WEST STREET, WEST BRIDGEWATER MA 02379
Nathan Lawrence other: VP Sales and Marketing 321 MANLEY STREET, WEST BRIDGEWATER MA 02379
Richard Thomley officer: Chief Financial Officer C/O PRESSURE BIOSCIENCES, INC., 14 NORFOLK AVE., SOUTH EASTON MA 02375
Kevin Pollack director 150 RAINVILLE ROAD, TARPON SPRINGS FL 34689
Michael S Urdea director 100 BUNCE MEADOWS DRIVE, ALAMO CA 94507
Alexander V Lazarev officer: VP of REsearch and Development 18 WINCHESTER DRIVE, LEXINGTON MA 02420
Edmund Y Ting officer: Senior VP of Engineering 23642 123RD PLACE SOUTHEAST, KENT WA 48031
Vito J Mangiardi director 12 POINT GALLINAS ROAD, SAN RAFAEL CA 94903
Jeffrey N Peterson director 1031 SHORELINE DRIVE, SAN MATEO CA 94404
Mir Conrad F officer: CFO 19 BRIER LANE, CLIFTON NJ 07012
Clayton A Struve 10 percent owner 175 W JACKSON BLVD, SUITE 440, CHICAGO IL 60604
Css Llc/il other: (a) 175 WEST JACKSON BLVD, SUITE 440, CHICAGO IL 60604
R Wayne Fritzsche director 835 GREENS PARKWAY, SUITE 150, HOUSTON TX 77067

Pressure BioSciences (Pressure BioSciences) Headlines

From GuruFocus